|
|
Epidemiology, comorbidities and quality of life in patients with psoriasis
Hugo, Jan ; Gkalpakiotis, Spyridon (advisor) ; Kodet, Ondřej (referee) ; Slonková, Veronika (referee)
Psoriasis is a complex systemic disease included among the Immune-Mediated Inflammatory Diseases (IMID). Although not life-threatening in itself, it has a dramatic impact on patients' quality of life and is associated with a risk of developing a number of comorbidities. Therefore, considering that it is one of the most common chronic dermatoses, affecting more than 100 million people worldwide, the WHO has designated psoriasis as a major global health problem. The goal of the treatment is to get the disease under long-term control, to achieve the fewest visible manifestations and minimal activity of new ones, while in patients with severe psoriasis, systemic therapy is necessary. However, this has been very difficult for a long time, because conventional systemic therapies were often not sufficiently effective, and due to side effects and the need for frequent laboratory tests, they were also not appropriate for long-term administration. Nevertheless, intensive research and a better understanding of the aetiopathogenesis of psoriasis have led to the development of targeted biological therapy, which represents a significant advance in both efficacy and safety. But it is a new therapy, so many questions are not yet answered, especially with newer generations of biological therapy. Therefore, our work...
|
guest ::
